AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04459377 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sodium Chloride 0.9% Inj
Description: Patients are randomized to three groups. Randomization in blocks of six patients stratified by sex. A list of serial numbers and randomized group affiliation is produced which is open to the pharmacy's manufacturing staff and closed to the staff of the trial. The pharmacy prepares filled syringes with investigation drug in accordance with randomized group affiliation.~All groups are sedated with midazolam intravenously to a defined end point. A syringe pump with volume accuracy ± 2% injects the test drug (P, K1 or K2). One infusion set is coupled between the syringe and a three-way connection, which in turn is connected to a peripheral venous catheter (PVK). This PVK is also used for blood sampling. Blood is sampled at two occasions. Directly preoperatively and two hours after surgery. The third molar is surgically removed.
Study NCT02246907 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Exercise
Description: All intervention patients will participate in an individualized prescriptive exercise intervention 2 to 4 times per week for a period of the induction chemotherapy/in-hospital recovery. The exercise intervention will begin on week 1 of the study, the day after the first batteries of initial assessments are concluded. Each exercise session will be divided into two parts. One part will be administered in the morning and the second one late in the afternoon. There will be a period of rest of at least 36 hours between each exercise session.
Study NCT03987516 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Active exercising
Description: Patients allocated to the experimental group were included in an active exercising program adapted to each patient
Study NCT04391114 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Traditional HoLEP
Description: Holmium laser enucleation of the prostate (HoLEP), first reported by Fraundorfer et al in 1998, is a more recent step in the evolution of holmium laser prostatectomy. HoLEP is a safe and effective procedure which has demonstrated comparable results to TURP and open prostatectomy for patients with symptomatic enlarged prostate, with low morbidity and short hospital stay \[4\]. The improvement in outcome parameters is durable, and the late complications and reoperation rates reported are very low \[5\]. HoLEP is equally suitable for small, medium and larger prostate glands, with clinical outcomes that are independent of prostate size, unlike TURP. HOLEP offers patients the alterative of being treated endoscopically with minimal blood loss, short catheterization time, and decreased hospital stay \[6\].
Study NCT04391114 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Top-Down HoLEP
Description: The main difference between the Top-Down and Traditional approach is that the direction of lateral dissection begins from upwards to downwards. This could help in avoiding the overtraction of the mucosal strip overlying the posterior urethral sphincter, which theoretically leads to a decrease in the incidence of postoperative stress incontinence. Moreover, using the Top-Down approach should lead to a decrease in the incidence of lost enucleation planes, which results in decreasing the intraoperative time and decreasing the number of cases required to master the HoLEP technique.
Study NCT02618902 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: tolerogenic dendritic cells (tolDC)
Description: dose-escalation
Study NCT02347306 — intervention group
Intervention type: OTHER
Intervention: Telephone interview
Study NCT04488029 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PCT
Description: PCT is designed to deliver similar therapy as is conventionally provided in-clinic by a Speech Language Pathologist (SLP), which the patient can access from any location using the application installed on a supported tablet. The device functions by allowing clinicians to create a personalized therapy program for each patient from 75 categories of clinical therapies, which patients may access from their tablet device remotely. The PCT software is comprised primarily of authentication and an algorithm that suggests advancement of the therapy program based on observed patient deficits and progress.
Study NCT03037138 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Blood flow Rate profiling
Description: Blood flow rate profiling during dialysis session
Study NCT01946152 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given PO
Study NCT01946152 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Filgrastim-sndz
Description: Given SC
Study NCT01946152 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01946152 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Description: Given PO
Study NCT04692519 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Duet Language Intervention Modules
Description: The Duet 2.0 intervention modules promote the following guiding principles that help build effective communication. Below are the 5 principles covered in the six Duet modules: 1) General Awareness: Awareness and knowledge of child development 2) Creating Opportunities: Opportunities for communication during everyday activities 3) Conversational Duets: Rhythmic and reciprocal early language interactions 4) Scaffolding: Providing just enough help to support child independence 5) Harmonizing: Using the strategies together. These modules, which include behavioral strategies, real-life and animated examples of high-quality early language interactions, and interactive scenarios. The modules were informed and narrated by community members and carefully designed to address specific needs of high-risk communities. The modules have also been translated into Spanish, making sure to encompass specific cultural and dialect needs. Translation accuracy was verified by a qualified Spanish translator.
Study NCT00994006 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Magnesium oxide
Description: 520 mg of elemental magnesium q.d.
Study NCT01487109 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CTP-499
Description: 600 mg tablet twice daily
Study NCT00994006 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Magnesium citrate
Description: Magnesium citrate , 98.6 mg of elemental magnesium t.i.d.
Study NCT01199224 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: veliparib
Description: veliparib formulation A
Study NCT01199224 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: veliparib
Description: veliparib formulation B
Study NCT01199224 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: veliparib
Description: veliparib formulation C
Study NCT02529163 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Late-life Schizophrenia ICP
Description: The ICP medication algorithms first trial begins with:~* Risperidone titrated to a max dose~Failure to Risperidone will lead to a second trial with either:~* Quetiapine OR Aripiprazole~If subject refuses or if this trial does not work, then offer:~* Ziprasidone or Loxapine~Failure of 2 anti-psychotic trials results in:~* Clozapine trial~If subject refuses a Clozapine trial then:~* Olanzapine offered~titrations occur over 33-36 day period (inpatient) or 12 week period (out patient) with each 0.5 mg titration after the target dose requiring a CGI-E~If compliance is an issue then a depot preparation:~* Paliperidone~* Risperidone~* Flupentixol~* Aripiprazole~Physicians will be prompted for non-pharmacological interventions
Study NCT02529163 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual
Description: The TAU group will be offered non-pharmacological interventions such as (but not limited to):~* metabolic monitoring~* skin hygiene~* pain management~* nutritional counseling~* family counselling~* Financial/housing support~* Group CBT (Cognitive Behavioral Therapy)~Physicians treating this group will use their own discretion as they will not be prompted like the ICP group.~Pharmacological interventions contain anti-psychotic medication selected at the discretion of the treating physician provided it fall under the current standard of care such as:~* Risperidone~* Aripiprazole~* Quetiapine~* Olanzapine~* Paliperidone~* Clozapine~* Ziprasidone~Max dosing and the time to reach the target dose is done at the discretion of the treating physician.
Study NCT00389493 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Risperidone
Description: Dosage of 0.5 mg to 4.0 mg per day as tolerated
Study NCT00389493 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exposure/ritual prevention therapy (EX/RP)
Description: EX/RP is a form of cognitive behavioral therapy. Participants assigned to EX/RP will attend therapy sessions twice per week. In EX/RP, participants will be exposed to feared objects or ideas, and will be encouraged not to carry out a compulsive response.
Study NCT00389493 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules will be identical in appearance to those of risperidone.
Study NCT00924768 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 20K EU CCRE
Description: Inhalation of CCRE
Study NCT04372823 — intervention group
Intervention type: BEHAVIORAL
Intervention: Policy/program
Description: Policy/program to improve nutrition and increase physical activity
Study NCT01487109 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo tablet
Study NCT02228148 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NFS
Description: Cochlear Nucleus Fitting Software
Study NCT02228148 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CSS
Description: Cochlear Nucleus Custom SoundTM Suite
Study NCT01729559 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5000 Units unfractionated Heparin Q 8 hr
Description: Venous thromboembolic prophylaxis medication
Study NCT01729559 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 30mg enoxaparin Q12 hr
Description: Venous thromboembolic prophylaxis
Study NCT01697124 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SPARK-EC
Description: The CIA study was a 5 month physical activity change intervention that utilized the SPARK-EC curriculum as the intervention. The SPARK-EC curriculum was designed to be a quality, comprehensive physical activity program for the preschool setting. Pre-and Post-intervention assessments were conducted
Study NCT06470126 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 2.5% NaOCl group: The interventions performed in the study are root- canal therapies and disinfection procedure of these therapies.
Description: 10 mL 2.5% NaOCl application followed the mechanical preparation. After 2 mL 0.9% saline application, the second samples were taken by placing a sterile cone in the largest canal of the tooth (distal canal for 60 seconds). The mesiobuccal and distobuccal canals were closed with a sterile cotton pellet while the samples were taken. After the application, the root canal filling was completed with a calcium hydroxide-containing paste (TgPex™, London, England), glass ionomer cement (Ionofil U, Voco, Cuxhaven, Germany) was placed, and the teeth were restored with a Stainless-Steel Crown (3M ESPE, Seefeld, Germany)
Study NCT06470126 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 0.9% sterile saline solution combined with 80 seconds: The OzonyTronX® interventions performed in the study are root- canal therapies and disinfection procedure of these therapies.
Description: The canals were irrigated with 10 mL 0.9% sterile saline. Ozone treatment (OzonyTronX with CA probe) was applied for 80 seconds, and 2 mL 0.9% saline application was performed. Finally, the second samples were taken by the method described in group with 2.5% NaOCl, and the canal treatment was completed.
Study NCT06470126 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 2.5% NaOCl with 80 seconds OzonyTronX®:The interventions performed in the study are root- canal therapies and disinfection procedure of these therapies.
Description: The disinfection of root canals was done using 10 mL, 2.5% NaOCl, and ozone treatment for 80 seconds, and 2 mL 0.9% saline application was performed. Finally, the second samples were taken by the method described in group with %2.5 NaOCl, and the canal treatment was completed.
Study NCT04111939 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Communities That HEAL
Description: The Communities That HEAL (CTH) intervention is a community-engaged intervention designed to increase the adoption of an integrated set of evidence-based practices delivered across healthcare, behavioral health, justice, and other community-based settings. It includes 3 components: community engagement to assist key stakeholders in applying evidence-based practices to addressing their opioid crisis, a menu of evidence-based practices for communities to select and implement, and a communications campaign to build demand for evidence-based practices to address overdose and opioid use disorder.
Study NCT00620724 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo three times daily
Study NCT00620724 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nifedipine
Description: 20 mg of slow-release Nifedipine three times daily
Study NCT02804126 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TAP (transversus abdominis plane block)
Description: ultrasound-guided regional block between abdominal wall muscles to treat acute postoperative pain. Stimuplex Ultra 360 needle will be used and 0.25% bupivacaine administered (0.2 mL/kg).
Study NCT02804126 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: QL (quadratus lumborum block)
Description: ultrasound-guided regional block between abdominal wall muscles to treat acute pain, similar to transversus abdominis plane block, but with distribution of local anesthetic towards paravertebral space. Stimuplex Ultra 360 needle will be used and 0.25% bupivacaine administered (0.2 mL/kg).
Study NCT02804126 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: In both groups (TAP\&QL) 0.25% bupivacaine will be given (0.2 mL/kg)
Study NCT02804126 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Needle
Description: Ultrasound-guided, Stimuplex ultra 360 needle will be used in the study
Study NCT02804126 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paracetamol
Description: Intravenous paracetamol will be used (1.0 gram), up to 4 grams per day
Study NCT04111939 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Wait-list control
Description: Communities in the wait-list control condition will continue usual care during the first 30 months of the trial. At month 31, Wave 2 communities will begin receiving the CTH intervention.
Study NCT02804126 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metamizol
Description: Intravenous metamizol will be used (1.0 gram), up to 4 grams per day
Study NCT02804126 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketoprofen
Description: Intravenous ketoprofen will be used (0.1 gram), up to 200 milligrams per day
Study NCT02804126 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine
Description: Intravenous morphine (5 mg) will be given when pain exceeds 40 mm in VAS (maximum 2 doses per day)
Study NCT04591158 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Butterfly iQ
Description: The Butterfly iQ is an ultrasound system that enable diagnostic ultrasound imaging and measurement of anatomical structures and fluids of adult and pediatric patients. It is a non-invasive device and does not impose any health hazards.
Study NCT02574273 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Secret Agent Society (SAS) Program
Description: The Secret Agent Society (SAS) intervention involves subjects participating in 9 weekly two-hour therapy groups ('Club meetings') with 3 to 6 other children. The SAS intervention includes a number of components to help children apply the skills that they learn in the session to home.
Study NCT04743999 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality of life questionnaire
Description: We will evaluate patients' quality of life with a series of questionnaires at baseline, 3, 6, 12, and 24 months after surgical staging. These are prospectively validated questionnaires and include FACT-G (physical and functional well-being sections), FACT-En (additional concerns section), FACT/GOG-NTX-4 (additional concerns section), and FACT-C (items C3 and C5).These sections will be combined into one single form for ease of completion for the patients (a total of 36 items).
Study NCT01555879 — intervention group
Intervention type: DRUG
Intervention: Abatacept
Description: As prescribed by a doctor for patient medical care.
Study NCT01961050 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dual-Focused Brief Physician Intervention (DFBPI)
Description: The DFBPI is incorporated in OB/GYN clinic visit. The intervention consists of two brief (5 to 10 minutes) manualized counseling segments delivered face-to-face by an OB/GYN in the context of two clinic visits.
Study NCT01961050 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Services as usual
Description: Active Comparator: Standard OB/GYN clinic visits that include OB/GYN services as usual.
Study NCT01101633 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Alginate
Description: a 500 ml alginate beverage per meal test
Study NCT02333942 — intervention group
Intervention type: DEVICE
Intervention: Nautilus NeuroWaveTM System
Description: A noninvasive device to detect dementia utilizing headset and sensors
Study NCT01977495 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Financial Incentive: Fixed Lottery
Description: Every day of the 91 day intervention period participants will be asked to use each of their biometric devices. A daily lottery will be conducted automatically by the study website. Participants must use each of their two devices daily to be eligible for the lottery the following day. Winning lottery numbers will be identified by a fixed-position match between the automatically generated winning number and a participant ID number, which each participant will pick at enrollment.
Study NCT00129389 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluorouracil
Description: Arm A: FAC Arm B: FAC-wP
Study NCT00129389 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: Arm A: FAC Arm B: FAC-wP
Study NCT00129389 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin
Description: Arm A: FAC Arm B: FAC-wP
Study NCT00129389 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Arm A: FAC Arm B: FAC-wP
Study NCT00129389 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: Arm A: FAC Arm B: FAC-wP
Study NCT00129389 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Arm A: FAC Arm B: FAC-wP
Study NCT00129389 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Arm B: FAC-wP
Study NCT01859338 — intervention group
Intervention type: RADIATION
Intervention: cone-beam computed tomography
Description: Undergo CBCT
Study NCT01859338 — intervention group
Intervention type: RADIATION
Intervention: magnetic resonance imaging
Description: Undergo MRI
Study NCT01859338 — intervention group
Intervention type: RADIATION
Intervention: computed tomography
Description: Undergo fan beam computed tomography
Study NCT01101633 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Alginate
Description: a 330 ml alginate beverage per meal test
Study NCT01101633 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: a 500 ml placebo beverage per meal test
Study NCT01101633 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: a 330 ml placebo beverage per meal test
Study NCT02700009 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computer-assisted CBT (CCBT)
Description: Computer-assisted psychotherapy for depression using a computer program plus clinician support
Study NCT02700009 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual (TAU)
Description: Ordinary treatment for depression in primary care setting
Study NCT03214471 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention
Description: Nutritional and behavioural tele-counselling , self-monitoring and a 12-week supervised tailored exercise programme. Participants will receive a regular tele-counselling throughout the 12-month. Each session will take approximately 15 minutes, underpinned by behavioural psychological techniques. After their 3-month post-surgery assessment visit, participants in the BARI-LIFESTYLE Intervention Study will be enrolled in a supervised exercise programme at health facility gyms for 12 weeks.
Study NCT04451720 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risankizumab
Description: Subcutaneous (SC) injection
Study NCT00991211 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: Comparison of Bendamustine + Rituximab with CHOP + Rituximab
Study NCT00991211 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard chemotherapy CHOP + Ritiximab
Description: Cyclophosphamid 750 mg/m² d 1 + Doxorubicin 50 mg/m² d 1 + Vincristin 1,4 mg/m² max. 2 mg d 1 + Prednison 100 mg absolute p.o. d 1-5 + Rituximab 375 mg/m² d 1 q3w as standard Chemotherapy
Study NCT02112565 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RNR inhibitor COH29
Description: Given PO
Study NCT02112565 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies